The $750m purchase price for Advanced BioHealing gives a 13 times return for Safeguard, which invested $26m.
London and Nasdaq-listed drugs maker Shire has agreed to buy Advanced BioHealing (ABH), which treats foot ulcers and is backed by medical device maker Safeguard Scientifics, for $750m in cash ahead of the target’s flotation.
The purchase price gives a 13 times return for Safeguard, which invested $26m in ABH alongside venture capital firms Canaan Partners, Wheatley Partners CDIB Bioscience Ventures, Channel Medical Partners, Horizon Technology Finance and Red Abbey Venture Partners.
In its filing ahead of listing, Safeguard owns…
